A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes

Prior treatment

• Known or suspected allergy to investigational drug products or related products; or a history of multiple and/or severe allergies to drugs or foods.
• Serious cardiovascular and cerebrovascular diseases within 6 months prior to screening.
• Participation in any clinical trial of an approved or unapproved investigational drug/medical device within 90 days prior to screening.

Other illness

• Positive test for hepatitis B surface antigen (HBsAg), HIV antibody, treponema pallidum specific antibody, or hepatitis C virus antibody; or the investigator judges that the subject is in the incubation or active phase of the above infection.
• Malignancy or history of malignancy within 5 years prior to screening.
• Any other condition judged by the investigator to be likely to affect the subject's safety or interfere with the evaluation of trial results.

Other

• Poor blood pressure control at screening.

• Informed consent obtained before any trial-related activities.
• Age 18\~59 years at screening (including cut-off values at both ends).
• Confirmed diagnosis of type 2 diabetes mellitus ≥ 6 months before screening.
• Female subjects of childbearing potential and their partners are male subjects of childbearing potential, who have no fertility plan and agree to take high-efficiency contraceptive measures within 3 months after signing the informed consent form and have no plans to donate eggs/sperm; Female subjects of childbearing potential have a negative pregnancy test during the screening period and are not lactating.